TRAMAZOLINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H17N3
Molecular Weight	215.2942
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C1CN=C(NC2=C3CCCCC3=CC=C2)N1

InChI

InChIKey=QQJLHRRUATVHED-UHFFFAOYSA-N

InChI=1S/C13H17N3/c1-2-6-11-10(4-1)5-3-7-12(11)16-13-14-8-9-15-13/h3,5,7H,1-2,4,6,8-9H2,(H2,14,15,16)

HIDE SMILES / InChI

Molecular Formula	C13H17N3
Molecular Weight	215.2942
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Tramazoline is a sympathomimetic drug that is used in the form of tramazoline hydrochloride in nasal decongestant preparations. Tramazoline is an α-adrenergic receptor agonist that inhibits secretion of nasal mucus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor alpha-2 113	Agonist 2,678		16.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rhinitis 20	Primary		Approved 8,429	Spray-Tish

PubMed

Show entries

Title	Date	PubMed
The effect of nasal steroid administration on intraocular pressure.	2007 Jul	17702318
Tramazoline turns asymptomatic into symptomatic hyper-CK-emia.	2007 Mar	17355540

Showing 1 to 2 of 2 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults and children six years of age and over is 1 to 2 sprays into each nostril up to four times daily as required.

Route of Administration: Nasal

In Vitro Use Guide

Binding affinity of Tramazoline against Alpha-2 adrenergic receptor measured as the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was 16 nM.